drugset
drugset / Trial / NCT02370602

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

NCT02370602 ↗

Phase 1 Completed 13 enrolled Takeda
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to estimate phosphodiesterase 10A (PDE10A) occupancy in brain following a single dose of TAK-063.

Timeline

Start
2013-10
Primary completion
2014-02
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject BALIPODECT Small molecule 3 mg Oral
Subject BALIPODECT Small molecule 10 mg Oral
Subject BALIPODECT Small molecule 30 mg Oral
Subject BALIPODECT Small molecule 100 mg Oral
Subject BALIPODECT Small molecule 1000 mg Oral
Subject [^11C]T-773 Unknown 400 mbq Intravenous

Indications

No indication recorded.